PortfoliosLab logoPortfoliosLab logo
IDEXX Laboratories, Inc. (IDXX)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US45168D1046
CUSIP
45168D104
IPO Date
Jun 21, 1991

Highlights

Market Cap
$45.33B
Enterprise Value
$45.30B
EPS (TTM)
$13.12
PE Ratio
42.84
PEG Ratio
9.76
Total Revenue (TTM)
$4.30B
Gross Profit (TTM)
$2.66B
EBITDA (TTM)
$1.47B
Year Range
$356.14 - $769.98
Target Price
$803.57
ROA (TTM)
31.62%
ROE (TTM)
65.99%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in IDEXX Laboratories, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

IDEXX Laboratories, Inc. (IDXX) has returned -16.95% so far this year and 33.80% over the past 12 months. Looking at the last ten years, IDXX has achieved an annualized return of 21.62%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.


IDEXX Laboratories, Inc.

1D
0.86%
1M
-14.44%
YTD
-16.95%
6M
-12.05%
1Y
33.80%
3Y*
3.96%
5Y*
2.93%
10Y*
21.62%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jun 24, 1991, IDXX's average daily return is +0.11%, while the average monthly return is +2.15%. At this rate, your investment would double in approximately 2.7 years.

Historically, 59% of months were positive and 41% were negative. The best month was Feb 2000 with a return of +96.3%, while the worst month was Mar 1997 at -62.4%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 5 months.

On a daily basis, IDXX closed higher 51% of trading days. The best single day was Aug 4, 2025 with a return of +27.5%, while the worst single day was Mar 24, 1997 at -62.5%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-0.90%-2.05%-14.44%-16.95%
20252.08%3.57%-3.93%3.02%18.65%4.48%-0.38%21.11%-1.27%-1.47%19.60%-10.14%63.63%
2024-7.20%11.68%-6.14%-8.74%0.85%-1.96%-2.27%1.09%4.96%-19.46%3.64%-1.97%-25.51%
202317.78%-1.51%5.67%-1.58%-5.57%8.06%10.45%-7.81%-14.50%-8.64%16.61%19.16%36.06%
2022-22.96%4.94%2.76%-21.31%-9.03%-10.44%13.81%-12.92%-6.28%10.40%18.40%-4.21%-38.04%
2021-4.24%8.67%-5.93%12.20%1.66%13.16%7.44%-0.70%-7.70%7.11%-8.72%8.29%31.73%

Benchmark Metrics

IDEXX Laboratories, Inc. has an annualized alpha of 20.01%, beta of 0.85, and R² of 0.15 versus S&P 500 Index. Calculated based on daily prices since June 25, 1991.

  • This stock captured 122.08% of S&P 500 Index gains but only 68.40% of its losses — a favorable profile for investors.
  • R² of 0.15 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
20.01%
Beta
0.85
0.15
Upside Capture
122.08%
Downside Capture
68.40%

Return for Risk

Risk / Return Rank

IDXX ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


IDXX Risk / Return Rank: 7070
Overall Rank
IDXX Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
IDXX Sortino Ratio Rank: 7474
Sortino Ratio Rank
IDXX Omega Ratio Rank: 7171
Omega Ratio Rank
IDXX Calmar Ratio Rank: 6767
Calmar Ratio Rank
IDXX Martin Ratio Rank: 7070
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for IDEXX Laboratories, Inc. (IDXX) and compare them to a chosen benchmark (S&P 500 Index).


IDXXBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.78

0.90

-0.12

Sortino ratio

Return per unit of downside risk

1.80

1.39

+0.42

Omega ratio

Gain probability vs. loss probability

1.23

1.21

+0.02

Calmar ratio

Return relative to maximum drawdown

1.28

1.40

-0.11

Martin ratio

Return relative to average drawdown

3.57

6.61

-3.04

Explore IDXX risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


IDEXX Laboratories, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the IDEXX Laboratories, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the IDEXX Laboratories, Inc. was 81.42%, occurring on Apr 18, 1997. Recovery took 1735 trading sessions.

The current IDEXX Laboratories, Inc. drawdown is 26.71%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-81.42%Feb 6, 1996304Apr 18, 19971735Mar 12, 20042039
-57.28%Nov 16, 2007256Nov 20, 2008356Apr 23, 2010612
-54%Aug 6, 2021301Oct 14, 2022765Nov 3, 20251066
-37.13%Feb 20, 202023Mar 23, 202032May 7, 202055
-35.34%Nov 11, 1991116Apr 27, 1992142Nov 16, 1992258

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of IDEXX Laboratories, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how IDEXX Laboratories, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for IDXX, comparing it with other companies in the Diagnostics & Research industry. Currently, IDXX has a P/E ratio of 42.8. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for IDXX compared to other companies in the Diagnostics & Research industry. IDXX currently has a PEG ratio of 9.8. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for IDXX relative to other companies in the Diagnostics & Research industry. Currently, IDXX has a P/S ratio of 10.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IDXX in comparison with other companies in the Diagnostics & Research industry. Currently, IDXX has a P/B value of 28.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items